Business
ADOCIA Announces THDB0206 (BioChaperone® Lispro) Phase 3 Data in Type 2 Diabetes Presented at ADA 86th Scientific Sessions, Confirming the Positive Results Previously Announced in July 2025
LYON, France, June 08, 2026--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, announces that the full results of the Phase 3 clinical study (Study THDB0206L02, NCT05834868) conducted on people with type 2 diabetes in China with BioChaperone® Lispro were presented at the American Diabetes Association (ADA) 86th Scientific S
About this update from Adocia Sa
LYON, France, June 08, 2026--(BUSINESS WIRE)--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, announces that the full results of the Phase 3 clinical study (Study THDB0206L02, NCT05834868) conducted on people with type 2 diabetes in China with BioChaperone® Lispro were presented at the American Diabetes Association (ADA) 86th Scientific Session (June 5-8, 2026 in New Orleans), completing the positive topline results of this clinical trial announced in July 20251. "Our Chinese partner Tonghua Dongbao reached a major milestone in July 2025: the phase 3 trial conducted in over 1,000 people living with type 2 diabetes confirmed the strong performance of BioChaperone® Lispro. For the first time, a prandial insulin demonstrates improved glycemic control in people with type 2 diabetes across all three daily meals compared with Humalog®, one of the world’s most widely used mealtime insulins," comments Olivier Soula, CEO and co-founder of Adocia. For more detail, the poster is accessible on Adocia’s website: https://www.adocia.com/medias-publications/?_categories=medias Webcast event Adocia will host a virtual Key Opinion Leader (KOL) event on Tuesday June 16, 2026 at 10:00 AM EST / 4:00 PM CEST. Tim Heise, MD (Profil, Neuss, Germany), will join company management, Olivier Soula, CEO and co-founder of Adocia and You-Ping Chan, Head of R&D, to review the results of the Phase 3 trial conducted in China on BioChaperone® Lispro for the treatment of type 2 diabetes. About Tim Heise, MD Tim Heise, MD is Lead Scientist, Chairman of the Board of Directors and co-founder of the private research institute Profil in Neuss, Germany. Profil has gained an international reputation for performing early-phase studies, in particular glucose clamp studies, investigating experimental diabetes treatments and medical devices. Dr. Heise has led numerous studies on the pharmacology of novel anti-diabetic agents and insulins. Before establishing Profil, Dr. Heise worked for more than 7 years at the Clinic for Nutrition and Metabolic Diseases at the Heinrich-Heine-University Düsseldorf (Head Prof Michael Berger). During this time, he was responsible for the diabetes and obesity outpatient clinics and t...